Joanne MD - CryoCell International Medical Board

CCEL Stock  USD 8.87  0.52  6.23%   

Insider

Joanne MD is Medical Board of CryoCell International
Address 700 Brooker Creek Boulevard, Oldsmar, FL, United States, 34677
Phone813 749 2100
Webhttps://www.cryo-cell.com

CryoCell International Management Efficiency

Return On Equity is expected to rise to 1.04 this year, although the value of Return On Tangible Assets are projected to rise to (0.14). At this time, CryoCell International's Asset Turnover is quite stable compared to the past year. CryoCell International's management efficiency ratios could be used to measure how well CryoCell International manages its routine affairs as well as how well it operates its assets and liabilities.
CryoCell International currently holds 10.9 M in liabilities with Debt to Equity (D/E) ratio of 0.26, which may suggest the company is not taking enough advantage from borrowing. CryoCell International has a current ratio of 0.46, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about CryoCell International's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Bradford HivelyOncology Institute
N/A
Brandon CPASonida Senior Living
43
Nikos NikolopoulosMednax Inc
51
Michael FryarSonida Senior Living
46
Beth RubioAveanna Healthcare Holdings
67
Brent GuerisoliPennant Group
43
W AdamsNational HealthCare
73
Dennis DeanAirsculpt Technologies
52
MD MBAOncology Institute
47
Vicki DodsonNational HealthCare
62
RN MHAInnovAge Holding Corp
73
Boxun ZhangConcord Medical Services
48
Denise WarrenBrookdale Senior Living
58
FACHE MBAOncology Institute
43
Barbara CPAInnovAge Holding Corp
61
Thomas McEachinMednax Inc
68
JD KennedyInnovAge Holding Corp
63
Shmuel LiebermanSonida Senior Living
N/A
Kevin BowmanBrookdale Senior Living
61
Liraz IsaacAirsculpt Technologies
N/A
Lee BienstockDocGo Inc
39
Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida. Cryo-Cell Intl operates under Medical Care Facilities classification in the United States and is traded on AMEX Exchange. It employs 83 people. CryoCell International (CCEL) is traded on NYSE MKT Exchange in USA. It is located in 700 Brooker Creek Boulevard, Oldsmar, FL, United States, 34677 and employs 82 people. CryoCell International is listed under Health Care Providers & Services category by Fama And French industry classification.

Management Performance

CryoCell International Leadership Team

Elected by the shareholders, the CryoCell International's board of directors comprises two types of representatives: CryoCell International inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CryoCell. The board's role is to monitor CryoCell International's management team and ensure that shareholders' interests are well served. CryoCell International's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CryoCell International's outside directors are responsible for providing unbiased perspectives on the board's policies.
Mark Portnoy, Co-CEO and Director
Jill Taymans, CFO and VP of Fin.
Joanne MD, Medical Board
Oleg Mikulinsky, Chief Officer
David Portnoy, Chairman and Co-CEO

CryoCell Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is CryoCell International a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether CryoCell International is a strong investment it is important to analyze CryoCell International's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact CryoCell International's future performance. For an informed investment choice regarding CryoCell Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CryoCell International. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.
For more information on how to buy CryoCell Stock please use our How to buy in CryoCell Stock guide.
You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CryoCell International. If investors know CryoCell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CryoCell International listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.625
Earnings Share
(1.07)
Revenue Per Share
3.89
Quarterly Revenue Growth
0.025
Return On Assets
(0)
The market value of CryoCell International is measured differently than its book value, which is the value of CryoCell that is recorded on the company's balance sheet. Investors also form their own opinion of CryoCell International's value that differs from its market value or its book value, called intrinsic value, which is CryoCell International's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CryoCell International's market value can be influenced by many factors that don't directly affect CryoCell International's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CryoCell International's value and its price as these two are different measures arrived at by different means. Investors typically determine if CryoCell International is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CryoCell International's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.